Displaying drugs 1201 - 1225 of 1993 in total
ONCOS‐102
Investigational
Roledumab
Roledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).
Investigational
Parsaclisib
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Investigational
Mazorelvimab
Investigational
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
AZD-0424
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
VM4-037
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
SOBI-003
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
YS-ON-001
YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
ETBX-051
Investigational
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
ABSK-091
Investigational
ABBV-011
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
SLC-0111
Investigational
ASTX-029
ASTX-029 is under investigation in clinical trial NCT03520075 (Study of ASTX029 in Subjects With Advanced Solid Tumors).
Investigational
QR-313
QR-313 is an antisense oligonucleotide targeting exon 73. It is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
Ivonescimab
Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).
Investigational
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
PI-0824
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids...
Investigational
TRU-015
Investigational
Displaying drugs 1201 - 1225 of 1993 in total